Authors' objectives: This is the pharmaceutical Joint Assessment PTJA07 – on ustekinumab for the treatment of ulcerative colitis (UC). In September 2019, EMA approved the extension of the indication for ustekinumab to include treatment of adult patients with moderately to severely active UC who have had an inadequate response with, lost response to or were intolerant to either conventional therapy or a biologic, or have medical contraindications to such therapies. This Joint Assessment aims to compare the clinical effectiveness and safety of ustekinumab in the target patient populations with relevant comparators (according to the national requirements of the EUnetHTA partners, the relevant comparators are adalimumab, infliximab, golimumab, vedolizumab, tofacitinib).

Project Status: Completed

URL for project: https://eunethta.eu/ptja07-ustekinumab-for-the-treatment-of-adult-patients-with-moderately-to-severely-active-ulcerative-colitis-uc-who-have-had-an-inadequate-response-with-lost-response-to-or-were-intoler/

Year Published: 2019

URL for published report: https://eunethta.eu/ptja07-ustekinumab-for-the-treatment-of-adult-patients-with-moderately-to-severely-active-ulcerative-colitis-uc-who-have-had-an-inadequate-response-with-lost-response-to-or-were-intoler/

English language abstract: An English language summary is available

Publication Type: Rapid Review

Organisation Name: European Network for Health Technology Assessment

Contact Email: eunethta@zinl.nl

Copyright: CC-BY-NC: You may copy, distribute, display, perform, and modify and use the EUnetHTA work for any purpose other than commercially unless you get your permission first.